EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Multi‐omics–driven precision medicine

Huibo Li iD, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su und 9 weitere

iMeta · 2026-10 · 5 (5)

DOI: 10.1002/imt2.70165 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift iMeta, online erschienen am 25.08.2026. Verfasst von Huibo Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and T…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 738 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision medicine is increasingly constrained not by a lack of molecular data but by the absence of frameworks that can translate multidimensional biological information into actionable clinical decisions. Multi‐omics‐driven precision medicine (MODPM) addresses this lack by integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome, and clinical context into a multiscale framework that links molecular mechanisms, tissue organization, and patient trajectories. In this review, we propose a conceptual framework for MODPM and examine how advances in multi‐omics technologies, artificial intelligence (AI), and foundation models are reshaping disease modeling, drug development, and precision intervention. We summarize the biological contributions of major omics layers and discuss how AI supports cross‐modal representation learning, contextual modeling, and perturbation‐aware prediction. We highlight drug development as a key translational application of MODPM and further discuss its clinical relevance across three major disease contexts: cancer, autoimmune diseases, and metabolic disorders, including cardiometabolic and renal–metabolic diseases. These examples illustrate how MODPM can support target discovery, disease endotyping, treatment response prediction, and clinical monitoring by analyzing shared mechanisms such as immune dysregulation, metabolic remodeling, chronic inflammation, tissue microenvironmental changes, and gene–environment interactions. Across these settings, MODPM enables finer molecular stratification, the identification of pathway‐dominant disease states, improved response prediction, and dynamic treatment monitoring. We also discuss key barriers to implementation, including data heterogeneity, limited cohort diversity, polygenic complexity, workflow constraints, cost, and ethical issues related to privacy, consent, and data ownership. Overall, the value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligenceclinical decision‐makingmulti‐omicsprecision medicinetranslational medicine

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine, Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology Macau SAR China.
  • Department of Pharmacy Peking University Third Hospital; Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center; Institute for Drug Evaluation, Peking University Health Science Center Beijing China.
  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University Beijing China.
  • Department of General Surgery Cancer Center, Peking University Third Hospital Beijing China.
  • Beijing Key Laboratory for Interdisciplinary Research in Gastrointestinal Oncology, Peking University Third Hospital Beijing China.
  • The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecula…

ORCID-Profile: Huibo Li, Lemin Zheng, Yi Zhun Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Zhao, Z., Zhang, Y., Ma, Y., Hu, G., Zeng, M., Yang, Z., Zhao, Z., Zhou, X., Hu, W., Sun, Y., Su, M., Li, J., Whiteman, M., Fu, W., Zhong, C., Zheng, L., Chen, L., Lv, H., …, & Zhu, Y. Z. (2026). Multi‐omics–driven precision medicine. iMeta, 5(5). https://doi.org/10.1002/imt2.70165

Vancouver

Li H, Zhao Z, Zhang Y, Ma Y, Hu G, Zeng M, et al. Multi‐omics–driven precision medicine. iMeta. 2026;5(5). doi:10.1002/imt2.70165

BibTeX
@article{Li2026,
  author = {Li, Huibo and Zhao, Zhe and Zhang, Yifan and Ma, Yao and Hu, Gaofei and Zeng, Min and Yang, Zhanqun and Zhao, Zixuan and Zhou, Xin and Hu, Wei and Sun, Yuxuan and Su, Meng and Li, Jun and Whiteman, Matthew and Fu, Wei and Zhong, Chao and Zheng, Lemin and Chen, Long and Lv, Hairong and Zhao, Rongsheng and Zhu, Yi Zhun},
  title = {Multi‐omics–driven precision medicine},
  journal = {iMeta},
  year = {2026},
  volume = {5},
  number = {5},
  doi = {10.1002/imt2.70165}
}
Kostenlos starten →